Study design (if review, criteria of inclusion for studies)
6-week double-blind, placebo-controlled, crossover trial
Participants
17 children with cystic fibrosis on pancreatic enzyme therapy
Interventions
misoprostol, 100 micrograms, four times a day
Outcome measures
efficacy (fat absorption)
Main results
In those patients who had greater than 90% absorption on enzyme therapy alone, no further significant increase in absorption was achieved with misoprostol administration. Those patients who had absorption of less than 90% on standard enzyme therapy showed a significant improvement with misoprostol administration (p less than 0.01). One patient had a significant elevation in the eosinophil count during the period of misoprostol administration, but there were no significant changes in any other hematological or biochemical parameter.
Authors' conclusions
Misoprostol appears to be of benefit to those children with cystic fibrosis who have residual malabsorption on standard enzyme therapy.